The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain

  1. Simon Mysling
  2. Kristian Kølby Kristensen
  3. Mikael Larsson
  4. Anne P Beigneux
  5. Henrik Gårdsvoll
  6. Fong G Loren
  7. André Bensadouen
  8. Thomas JD Jørgensen
  9. Stephen G Young
  10. Michael Ploug  Is a corresponding author
  1. Rigshospitalet, Denmark
  2. University of California, Los Angeles, United States
  3. Rigshospitalet, United States
  4. Cornell University, United States
  5. University of Southern Denmark, Denmark

Abstract

GPIHBP1 is a glycolipid-anchored membrane protein of capillary endothelial cells that binds lipoprotein lipase (LPL) within the interstitial space and shuttles it to the capillary lumen. The LPL•GPIHBP1 complex is responsible for margination of triglyceride-rich lipoproteins along capillaries and their lipolytic processing. The current work conceptualizes a model for the GPIHBP1•LPL interaction based on biophysical measurements with hydrogen-deuterium exchange/mass spectrometry, surface plasmon resonance, and zero-length cross-linking. According to this model, GPIHBP1 is comprised of two functionally distinct domains: (1) an intrinsically disordered acidic N-terminal domain; and (2) a folded C-terminal domain that tethers GPIHBP1 to the cell membrane by glycosylphosphatidylinositol. We demonstrate that these domains serve different roles in regulating the kinetics of LPL binding. Importantly, the acidic domain stabilizes LPL catalytic activity by mitigating the global unfolding of LPL's catalytic domain. This study provides a conceptual framework for understanding intravascular lipolysis and GPIHBP1 and LPL mutations causing familial chylomicronemia.

Article and author information

Author details

  1. Simon Mysling

    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  2. Kristian Kølby Kristensen

    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  3. Mikael Larsson

    Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    No competing interests declared.
  4. Anne P Beigneux

    Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    No competing interests declared.
  5. Henrik Gårdsvoll

    Finsen Laboratory, Rigshospitalet, Copenhagen, United States
    Competing interests
    No competing interests declared.
  6. Fong G Loren

    Department of Medicine, University of California, Los Angeles, Loa Angeles, United States
    Competing interests
    No competing interests declared.
  7. André Bensadouen

    Division of Nutritional Science, Cornell University, Ithaca, United States
    Competing interests
    No competing interests declared.
  8. Thomas JD Jørgensen

    Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
    Competing interests
    No competing interests declared.
  9. Stephen G Young

    Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    Stephen G Young, Reviewing editor, eLife.
  10. Michael Ploug

    Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    For correspondence
    m-ploug@finsenlab.dk
    Competing interests
    No competing interests declared.

Copyright

© 2016, Mysling et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,213
    views
  • 547
    downloads
  • 63
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Simon Mysling
  2. Kristian Kølby Kristensen
  3. Mikael Larsson
  4. Anne P Beigneux
  5. Henrik Gårdsvoll
  6. Fong G Loren
  7. André Bensadouen
  8. Thomas JD Jørgensen
  9. Stephen G Young
  10. Michael Ploug
(2016)
The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain
eLife 5:e12095.
https://doi.org/10.7554/eLife.12095

Share this article

https://doi.org/10.7554/eLife.12095

Further reading

    1. Structural Biology and Molecular Biophysics
    Jinsai Shang, Douglas J Kojetin
    Research Advance

    Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor transcription factor that regulates gene expression programs in response to ligand binding. Endogenous and synthetic ligands, including covalent antagonist inhibitors GW9662 and T0070907, are thought to compete for the orthosteric pocket in the ligand-binding domain (LBD). However, we previously showed that synthetic PPARγ ligands can cooperatively cobind with and reposition a bound endogenous orthosteric ligand to an alternate site, synergistically regulating PPARγ structure and function (Shang et al., 2018). Here, we reveal the structural mechanism of cobinding between a synthetic covalent antagonist inhibitor with other synthetic ligands. Biochemical and NMR data show that covalent inhibitors weaken—but do not prevent—the binding of other ligands via an allosteric mechanism, rather than direct ligand clashing, by shifting the LBD ensemble toward a transcriptionally repressive conformation, which structurally clashes with orthosteric ligand binding. Crystal structures reveal different cobinding mechanisms including alternate site binding to unexpectedly adopting an orthosteric binding mode by altering the covalent inhibitor binding pose. Our findings highlight the significant flexibility of the PPARγ orthosteric pocket, its ability to accommodate multiple ligands, and demonstrate that GW9662 and T0070907 should not be used as chemical tools to inhibit ligand binding to PPARγ.

    1. Structural Biology and Molecular Biophysics
    Yuanyuan Wang, Fan Xu ... Yongning He
    Research Article

    SCARF1 (scavenger receptor class F member 1, SREC-1 or SR-F1) is a type I transmembrane protein that recognizes multiple endogenous and exogenous ligands such as modified low-density lipoproteins (LDLs) and is important for maintaining homeostasis and immunity. But the structural information and the mechanisms of ligand recognition of SCARF1 are largely unavailable. Here, we solve the crystal structures of the N-terminal fragments of human SCARF1, which show that SCARF1 forms homodimers and its epidermal growth factor (EGF)-like domains adopt a long-curved conformation. Then, we examine the interactions of SCARF1 with lipoproteins and are able to identify a region on SCARF1 for recognizing modified LDLs. The mutagenesis data show that the positively charged residues in the region are crucial for the interaction of SCARF1 with modified LDLs, which is confirmed by making chimeric molecules of SCARF1 and SCARF2. In addition, teichoic acids, a cell wall polymer expressed on the surface of gram-positive bacteria, are able to inhibit the interactions of modified LDLs with SCARF1, suggesting the ligand binding sites of SCARF1 might be shared for some of its scavenging targets. Overall, these results provide mechanistic insights into SCARF1 and its interactions with the ligands, which are important for understanding its physiological roles in homeostasis and the related diseases.